Literature DB >> 354148

Estrogen receptors and post-receptor markers in human breast cancer: a reappraisal.

I Nenci, M D Beccati, C A Pagnini.   

Abstract

Several major defects in the estrogen receptor pathway have been evidenced in most human breast cancers by an immunofluorescence tracing of estradiol receptor complexes at the single cell level. Endogenous peroxidase seems a reliable postreceptor marker for estrogen-sensitive breast cancer cells. Since almost all human breast cancers appear to include both hormone-sensitive and autonomous cell populations, a combined use of endocrine and cytotoxic regimens is urged. The hormonal regulation of tumor growth parameters could be exploited in order to achieve a maximum recruitment of synchronized tumor cells at risk to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 354148     DOI: 10.1177/030089167806400206

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  5 in total

1.  Cytochemistry of sex steroid receptors: a critique.

Authors:  K S McCarty; D S Reintgen; H F Seigler; K S McCarty
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

2.  Papillary hidradenoma: immunohistochemical analysis of steroid receptor profile with a focus on apocrine differentiation.

Authors:  A Offidani; A Campanati
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

3.  Fluorescent ligands, used in histocytochemistry, do not discriminate between estrogen receptor-positive and receptor-negative human tumor cell lines.

Authors:  E M Berns; E Mulder; F F Rommerts; R A Blankenstein; E de Graaf; H J van der Molen
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

4.  Oestradiol-BSA conjugates for receptor histochemistry: problems of stability and interactions with cytosol.

Authors:  M Binder
Journal:  Histochem J       Date:  1984-09

5.  Immunofluorescent detection of hormone receptors in cutaneous melanocytic tumours.

Authors:  A J Thompson; M G Cook; P G Gill
Journal:  Br J Cancer       Date:  1981-05       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.